This article summarises a presentation by Dr Ulka Vaishampayanon at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this week on a personalised approach to the systemic treatment of renal cell carcinoma (RCC). Dr Vaishampayanon focuses on systemic therapy advances in RCC management, the role of cytoreductive nephrectomy in RCC, and biomarkers in RCC.

Read more in UroToday here